Morgan Stanley’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-62,223
Closed -$1.12M 6857
2017
Q4
$1.12M Sell
62,223
-95,109
-60% -$1.17M ﹤0.01% 4463
2017
Q3
$1.86M Buy
157,332
+7,369
+5% +$82.7K ﹤0.01% 3958
2017
Q2
$1.57M Buy
149,963
+44,840
+43% +$457K ﹤0.01% 4003
2017
Q1
$1.16M Sell
105,123
-278,818
-73% -$3.24M ﹤0.01% 4275
2016
Q4
$5.2M Buy
383,941
+266,302
+226% +$3.72M ﹤0.01% 2945
2016
Q3
$1.45M Sell
117,639
-198,560
-63% -$2.34M ﹤0.01% 3753
2016
Q2
$3.47M Buy
316,199
+61,705
+24% +$691K ﹤0.01% 2937
2016
Q1
$2.78M Buy
254,494
+205,115
+415% +$2.59M ﹤0.01% 3070
2015
Q4
$854K Sell
49,379
-457,955
-90% -$8.21M ﹤0.01% 4179
2015
Q3
$10.1M Buy
507,334
+262,128
+107% +$6.01M ﹤0.01% 1942
2015
Q2
$4.03M Sell
245,206
-130,206
-35% -$2.26M ﹤0.01% 2991
2015
Q1
$5.84M Buy
375,412
+240,690
+179% +$3.73M ﹤0.01% 2617
2014
Q4
$1.93M Buy
134,722
+127,522
+1,771% +$1.35M ﹤0.01% 3597
2014
Q3
$47K Sell
7,200
-12,520
-63% -$83.2K ﹤0.01% 5751
2014
Q2
$137K Sell
19,720
-31,883
-62% -$225K ﹤0.01% 5346
2014
Q1
$369K Buy
51,603
+40,292
+356% +$345K ﹤0.01% 4762
2013
Q4
$106K Sell
11,311
-24,764
-69% -$177K ﹤0.01% 5331
2013
Q3
$225K Buy
36,075
+14,475
+67% +$90.4K ﹤0.01% 4810
2013
Q2
$142K Buy
+21,600
New +$171K ﹤0.01% 4983

Other funds holding SCMP

Morgan Stanley's SCMP Position: Q1 2018 in Review

Morgan Stanley sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 62,223 shares — an estimated $1.12M sold.

Morgan Stanley first reported a position in SCMP in Q2 2013 and held it in 19 quarters. The position peaked at $10.1M in Q3 2015. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Morgan Stanley reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Morgan Stanley sold 62,223 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.12M.
  • Morgan Stanley first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
  • Morgan Stanley's Sucampo Pharmaceuticals, Inc. position peaked at $10.1M in Q3 2015.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Morgan Stanley's 13F filing for Q1 2018, filed 14 May 2018.